A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASOCITINIB (TAK-279) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS STRATIFIED BY PRIOR BIOLOGIC USE (LATITUDE-PSA- 3002)

Registry ID

TAK-279-PSA-3002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

TAKEDA DEVELOPMENT CENTER AMERICAS INC

Start date

2025-12-16

Last update

2025-03-05

Conditions

• ACTIVE PSORIATIC ARTHRITIS

Related clinical trials

• A PHASE 2 MULTICENTER, RANDOMIZED, PLATFORM STUDY OF TARGETED THERAPIES FOR THE TREATMENT OF ADULT SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF JNJ-77242113 FOR THE TREATMENT OF BIOLOGIC-EXPERIENCED AND BIOLOGIC-NAÏVE PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS
• A PHASE 3, PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, 3-ARM, PLACEBOCONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS SONELOKIMAB IN MALE AND FEMALE PARTICIPANTS AGED 18 YEARS AND OVER WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE NAIVE TO BIOLOGIC DMARDS
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2B/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IZOKIBEP IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
• A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF SUBCUTANEOUSLY ADMINISTERED GUSELKUMAB IN IMPROVING THE SIGNS AND SYMPTOMS AND INHIBITING RADIOGRAPHIC PROGRESSION IN PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS (APEX)
• A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP 690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

View on source registry